Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
ENOV · against 588 other Healthcare companies listed in US-listed
Ranked #80 of 589 · scores higher than 86% of peers
Bars: peers in each 10-point band of the valuation score31 peers with a valuation score of 70–79, including ENOV · Click a bar to see the companies
Mainly thanks to its EBITDA yield and free cash flow yield, which are stronger than most Healthcare peers.
| Metric | ENOV | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | -92.1% | -4.3% | 5% | 30% | |
| EBITDA yieldHigher is better · 578 reported | 14.8% | -0.8% | 93% | 50% | |
| Free cash flow yieldHigher is better · 553 reported | 5.3% | -2.3% | 84% | 20% | |
| Book yieldHigher is better · 587 reported | 122.6% | 25.9% | 94% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 256M USD | 98 | 80 | |
| 2 | 595M USD | 96 | 97 | |
| 2 | 433M USD | 96 | 81 | |
| 2 | 289M USD | 96 | 57 | |
| 2 | 810M USD | 96 | 69 | |
| 76 | 561M USD | 72 | 74 | |
| 79 | 1.3B USD | 71 | 29 | |
| 80 | 11.6B USD | 70 | 56 | |
| 80 | 116.9B USD | 70 | 47 | |
| 80 | 1.2B USD | 70 | 46 | |
| 80 | 27.8B USD | 70 | 55 | |
| 80 | 4.6B USD | 70 | 61 | |
| 80 | 2.3B USD | 70 | 67 | |
| 80 | 25.8B USD | 70 | 75 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score